JADE MONO-2 Study Results: Efficacy and Safety of Abrocitinib in Patients With Moderate to Severe Atopic Dermatitis

From the 2020 Annual Meetings of the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American Academy of Dermatology (AAD), and Revolutionizing Atopic Dermatitis (RAD).
Moderate to severe atopic dermatitis was significantly improved for adolescents and adults treated with abrocitinib vs placebo.
Format: Microsoft PowerPoint (.ppt)
File Size: 210 KB
Released: July 20, 2020

Acknowledgements

Provided by Clinical Care Options.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This educational activity is supported by educational grants from
AbbVie Inc.
Pfizer Inc.

Related Content

Expert slides from Clinical Care Options (CCO) on optimal management of inflammatory bowel disease (IBD), including ulcerative colitis, Crohn disease

Uma Mahadevan, MD William Sandborn, MD Released: September 22, 2020

Efficacy, safety of baricitinib in patients with moderate to severe atopic dermatitis in BREEZE-AD5: atopic dermatitis conference coverage from CCO

Released: August 11, 2020

Enter asthma patient characteristics in this online CCO tool and compare your treatment plan with those of 5 experts

Michael E. Wechsler, MD, MMSc
Program Director
Bradley E. Chipps, MDFAAP, FACAAI, FAAAAI, FCCP Nicola Alexander Hanania, MD, MS Linda Rogers, MD Eileen Wang, MD, MPH
Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: August 5, 2020 Expired: August 4, 2021

Effect of withdrawal and retreatment with upadacitinib during an interim analysis of the 88-week phase 2b trial, from CCO

Released: July 27, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue